Why Omeros Stock Skyrocketed Today
For the most part, the stock market tends to be sedate in the late holiday season. That sure wasn't the case on Wednesday with (NASDAQ: OMER), which saw a nearly 76% share price leap after its leading pipeline drug earned U.S. Food and Drug Administration (FDA) approval.
The FDA's nod came that morning, with the regulator approving Omeros's Yartemlea for hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA), a potentially fatal complication from stem cell transplants. This is the first and only FDA-approved TA-TMA treatment.
Image source: Getty Images.
Source Fool.com
Omeros Corp. Aktie
10,05 €
4,69 %
Omeros Corp. ist derzeit einer der Favoriten unserer Community mit 20 Buy-Einschätzungen und keiner einzigen Sell-Einschätzung.
Mit einem Community-Kursziel von 30 € für Omeros Corp. wird ein starkes Wachstumspotenzial gegenüber dem aktuellen Kurs von 10.05 € gesehen.
